Global Stroke Prevention in Atrial Fibrillation Market 2017-2024: Survey of 213 Cardiologists in the US, Japan, and Five Major EU markets Sheds Light on Prescribing Trends in SPAF.

DUBLIN, Feb. 16, 2018 /PRNewswire/ --

The "Stroke prevention in Atrial Fibrillation Market and Forecast Analysis to 2024" report has been added to's offering.

Atrial fibrillation is the most common chronic cardiac arrhythmia, and is usually associated with other cardiovascular diseases. Atrial fibrillation is characterized by an irregular heartbeat, where the atria may not contract properly. While the disease is not considered life-threatening in itself, atrial fibrillation is one of the leading causes of stroke, with the disease conferring a fivefold increased risk.

Market Snapshot

    --  The approval of antidotes for the novel oral anticoagulants will play a
        major role in increasing uptake of these drugs.
    --  Survey of 213 cardiologists in the US, Japan, and five major EU markets
        sheds light on prescribing trends in SPAF.
    --  Diagnosed prevalent cases of atrial fibrillation are estimated to
        increase by more than 40% during the forecast period.
    --  Eliquis's low bleeding risk and strong efficacy results in SPAF patients
        will likely help to increase the uptake of the medication.
    --  Drug developers will need to identify reversal agents in order for
        pipeline medications to be able to compete with marketed drugs.
    --  EU payers limit use due to high cost, while US payers support uptake.

Key Topics Covered:

Forecast: Stroke Prevention In Atrial Fibrillation

    --  Market Overview And Trends
    --  Market Definition And Methodology
    --  Eliquis (Apixaban)
    --  Pradaxa (Dabigatran)
    --  Savaysa (Edoxaban)
    --  Xarelto (Rivaroxaban)

Treatment: Stroke Prevention In Atrial Fibrillation

    --  Primary Research Methodology
    --  Disease Definition And Diagnosis
    --  Current Treatment Options
    --  Prescribing Trends

Epidemiology: Atrial Fibrillation

    --  Disease Background
    --  Methodology
    --  Forecast
    --  Epidemiologist Insight
    --  Strengths And Limitations
    --  Bibliography
    --  Appendix: Additional Sources

Marketed Drugs: Stroke Prevention In Atrial Fibrillation

    --  Product Overview
    --  Product Profile: Eliquis
    --  Product Profile: Pradaxa
    --  Product Profile: Savaysa
    --  Product Profile: Xarelto

Noacs Pricing, Reimbursement, And Access

    --  Regulatory Labels
    --  Global Payer And Key Opinion Leader Insights
    --  Us Pricing
    --  Us Reimbursement
    --  Japan
    --  Pricing In The Five Major Eu Markets
    --  France
    --  Germany
    --  Italy
    --  Spain
    --  UK
    --  Methodology

Pipeline: Stroke Prevention In Atrial Fibrillation

    --  Executive Summary

    --  Pipeline Trends

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets